"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me ...

In this uncontrolled environment, the pathological cascade of Alzheimer’s begins, with the formation of beta-amyloid protein ...

June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

INmune Bio's XPro1595 targets soluble TNF for Alzheimer's. Phase 2 results could reshape inflammatory disease treatment.

Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has ...

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, accessible and inexpensive than other existing tests.

For decades, the theory that has dominated Alzheimer’s research, and drug pipelines, is known as the amyloid hypothesis ...

The loss of a certain immune-regulating protein in the brain leads to a decrease in the levels of amyloid beta, which causes Alzheimer's disease, and improves cognitive function, a group of ...

Lecanemab and donanemab are monoclonal antibody drugs that remove amyloid beta from the brain. Wilcock said in an email to the DCNF that the Lesné paper “only briefly influenced the field.” ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in ...